Werewolf Therapeutics, Inc. — Director's Dealing 2021

Jul 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2021-07-01

Reporting Person: Karunatilake Chulani (Chief Technology Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-01	Stock Option (right to buy)	$19.23	A	272000	Acquired	2031-06-30	Common Stock (272000.0)	Direct

Footnotes

F1: The option was granted on July 1, 2021. The shares underlying the option vest over four years, with one-fourth of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter.